Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00936741 · ClinicalTrials.gov registry record · Phase 3
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
A Phase 3 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00936741 is a Phase 3 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT00936741, a Phase 3 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome. Total treatment duration may be up to 12 months or longer at the discretion of the Investigator.
Interventions
- DRUG mifepristone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00936741
The ClinicalTrials.gov registry entry for NCT00936741 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which mifepristone is the first listed.
NCT00936741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00936741 about?
NCT00936741 is a clinical study titled "An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome". Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome. Total treatment duration may be up to 12 months or longer at the discreti...
What is the current status of trial NCT00936741?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2009-07. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00936741?
The interventions under investigation include: mifepristone (DRUG).
Who is sponsoring clinical trial NCT00936741?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.